PLETHICO PHARMACEUTICALS LTD.

NSE : NABSE : 532739ISIN CODE : INE491H01018Industry : Pharmaceuticals & DrugsHouse : Private
BSE7.940 (0 %)
PREV CLOSE ( ) 7.94
OPEN PRICE ( ) 8.30
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 10351
TODAY'S LOW / HIGH ( )7.94 8.30
52 WK LOW / HIGH ( ) 7.948.3
NSE
This Company is not listed in NSE
( in Million)
Select year
ParticularsMar2014Dec2012Dec2011Dec2010Dec2009
Profit Before Tax968.481092.771941.922555.351940.00
Adjustment2240.43797.691021.18589.72483.97
Changes In working Capital-910.08-2578.69-5491.79-1293.96-802.87
Cash Flow after changes in Working Capital2298.83-688.23-2528.691851.111621.10
Cash Flow from Operating Activities2437.35-610.11-2716.741763.981654.21
Cash Flow from Investing Activities-6264.6575.23-996.91-847.32-334.45
Cash Flow from Financing Activities2490.09-405.103566.87-853.07-1231.70
Net Cash Inflow / Outflow-1337.21-939.98-146.7863.5988.06
Opening Cash & Cash Equivalents315.671104.04405.37504.03464.41
Cash & Cash Equivalent on Amalgamation / Take over / MergerNANANANANA
Cash & Cash Equivalent of Subsidiaries under liquidationsNANANANANA
Translation adjustment on reserves / op cash balalces frgn subsidiariesNANANANANA
Effect of Foreign Exchange Fluctuations1361.69151.61845.45-162.25-48.44
Closing Cash & Cash Equivalent340.15315.671104.04405.37504.03

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.